Glucose Disposal Rate as a Metric for Detection of Metabolic Associated Fatty Liver
NCT ID: NCT06923215
Last Updated: 2025-04-11
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
NOT_YET_RECRUITING
30 participants
OBSERVATIONAL
2025-07-30
2026-12-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Change of Glucose Metabolism and Fibrosis Markers in Patients With Hepatitis C Under Treatment With Antiviral Agents
NCT03908294
Association of Non-alcoholic Fatty Liver Disease and Diabetes Mellitus
NCT01997424
Point-of-care Ultrasound Screening and Assessment of Chronic Liver Diseases and NASH
NCT05120557
Effect of Thyroid Disorders in Liver Diseases
NCT06071923
Assessment of Nonalcoholic Fatty Liver Disease in Diabetic and Prediabetic Patients Using Noninvasive Methods.
NCT04553796
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Determine eGDR's diagnostic accuracy for MAFLD using FibroScan® (CAP ≥248 dB/m) as the gold standard.
Secondary Aims
Correlate eGDR with MAFLD severity (steatosis via CAP, fibrosis via liver stiffness measurement \[LSM\]).
Compare eGDR's performance to Fatty Liver Index (FLI) and FIB-4 in detecting MAFLD and predicting fibrosis.
Identify optimal eGDR cut-offs for MAFLD detection (\<6 mg/kg/min) and advanced fibrosis staging (\<4 mg/kg/min).
Evaluate eGDR's reclassification improvement (net reclassification index \>10%) over existing scores.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
CROSS_SECTIONAL
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Adults with suspected/confirmed metabolic syndrome
Adults (18-65 years) with suspected/confirmed metabolic syndrome (IDF criteria) attending a metabolic clinic in Egypt over 12 months. Exclusions include other liver diseases, high alcohol intake, pregnancy, or advanced cirrhosis.
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Suspected/confirmed MS per IDF criteria:
* Central obesity (waist circumference ≥94 cm \[men\]/≥80 cm \[women\]) plus ≥2 of: Triglycerides ≥150 mg/dL.
HDL \<40 mg/dL (men)/\<50 mg/dL (women). Blood pressure ≥130/85 mmHg or antihypertensive treatment. Fasting glucose ≥100 mg/dL or diabetes diagnosis.
Exclusion Criteria
Alcohol intake \>20 g/day (men) or \>10 g/day (women).
Pregnancy, malignancy, advanced cirrhosis.
Medications affecting metabolism (e.g., steroids)
18 Years
65 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Assiut University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Amira William Ayad Makar
resident at the tropical medicine and gastroenterology in Assuit university.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Glucose Disposal Rate in MAFLD
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.